-
公开(公告)号：US20210333281A1
公开(公告)日：2021-10-28
申请号：US17282218
申请日：2019-10-02
IPC分类号： G01N33/574 , A61K31/47 , A61P35/00 , C12Q1/6886
摘要： Biomarkers are provided that predict whether a subject having a hepatocellular carcinoma is responsive to a therapy comprising soratenib or a pharmaceutically acceptable salt thereof. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing a hepatocellular carcinoma.
-
公开(公告)号：US10945990B2
公开(公告)日：2021-03-16
申请号：US15554540
申请日：2016-03-03
发明人： Junji Matsui , Gursel Aktan , Vassiliki Karantza , RuiRong Yuan , Yasuhiro Funahashi , Erhan Berrak
IPC分类号： A61K31/357 , A61K45/06 , A61K39/395 , A61K9/00 , C07K16/28
摘要： The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.
-
3.发明申请BIOMARKERS FOR PREDICTING AND ASSESSING RESPONSIVENESS OF ENDOMETRIAL CANCER SUBJECTS TO LENVATINIB COMPOUNDS 审中-公开生物标志物预测和评估内膜癌患者对列萘醌化合物的反应公开(公告)号：US20160089366A1
公开(公告)日：2016-03-31
申请号：US14890207
申请日：2014-05-12
IPC分类号： A61K31/47 , G01N33/574
CPC分类号： A61K31/47 , G01N33/57442 , G01N2333/475 , G01N2333/515 , G01N2800/52
摘要： Biomarkers are provided that predict whether a subject having endometrial cancer will or will not respond to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing an endometrial cancer.
摘要翻译： 提供了生物标志物，其预测具有子宫内膜癌的受试者是否会对包含联苯卡因或其药学上可接受的盐（例如甲磺酸伦伐他汀）的治疗作出反应。 本文描述的生物标志物，组合物和方法可用于选择具有怀疑具有或有发展子宫内膜癌风险的受试者的适当治疗方式。
-
4.发明申请公开(公告)号：US20180209980A1
公开(公告)日：2018-07-26
申请号：US15934242
申请日：2018-03-23
发明人： Yasuhiro Funahashi , Tadashi Kadowaki , Junji Matsui , Jason S. Simon , Lucy Xu
IPC分类号： G01N33/574 , C12Q1/6886 , A61K31/47
CPC分类号： G01N33/57407 , A61K31/47 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , G01N33/57438
摘要： Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.
-
公开(公告)号：US20140148483A1
公开(公告)日：2014-05-29
申请号：US14117276
申请日：2012-05-16
发明人： Taro Semba , Yusuke Narita , Yukinori Minoshima , Atsumi Yamaguchi , Yusuke Adachi , Kazuhiko Yamada , Junji Matsui , Tadashi Kadowaki , Kentaro Takahashi , Yasuhiro Funahashi
CPC分类号： C12Q1/6886 , A61K31/4025 , A61K31/404 , A61K31/47 , A61K31/517 , C12Q2600/106 , C12Q2600/112 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G01N33/574 , G01N33/5748 , G01N33/57488 , G01N33/57496 , G01N2333/515 , G01N2333/82 , G01N2333/916 , G01N2800/52
摘要： The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.
摘要翻译： 本发明的目的是提供一种用于预测患有肿瘤的受试者中血管生成抑制剂的有效性的方法。 提供了一种方法，其包括测试来自受试者的肿瘤组织样品中是否存在B-Raf和PTEN的突变或丧失的表达的存在或不存在的步骤。 通过使用B-Raf和PTEN的表达的存在或不存在或突变或丧失作为指标，该方法能够预测血管生成抑制剂的抗肿瘤效力，而不向受试者施用血管生成抑制剂。
-
公开(公告)号：US20210349097A1
公开(公告)日：2021-11-11
申请号：US17282193
申请日：2019-10-02
发明人： Yasuhiro Funahashi , Yukinori Minoshima , Michio Kanekiyo , Masahiro Matsuki , Yusuke Adachi , Kotaro Kodama
IPC分类号： G01N33/574 , A61P35/04 , A61K31/47 , A61K31/436 , C12Q1/6886
摘要： Biomarkers are provided that predict whether a human subject having a renal cell carcinoma is responsive to a combination therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate) and everolimus. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing a renal cell carcinoma.
-
公开(公告)号：US11083705B2
公开(公告)日：2021-08-10
申请号：US16835719
申请日：2020-03-31
发明人： Taro Semba , Yasuhiro Funahashi
IPC分类号： A61K31/357 , A61K9/127 , A61P35/00 , C07K16/28 , A61P35/04
摘要： Disclosed herein is a method for treating tumor, comprising administering a liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist to a patient in need thereof.
-
公开(公告)号：US20230212679A1
公开(公告)日：2023-07-06
申请号：US17692698
申请日：2022-03-11
发明人： Taro Semba , Yusuke Narita , Yukinori Minoshima , Atsumi Yamaguchi , Yusuke Adachi , Kazuhiko Yamada , Junji Matsui , Tadashi Kadowaki , Kentaro Takahashi , Yasuhiro Funahashi
IPC分类号： C12Q1/6886 , A61K31/47 , G01N33/574 , A61K31/517 , A61K31/404 , A61K31/4025
CPC分类号： C12Q1/6886 , A61K31/47 , A61K31/404 , A61K31/517 , A61K31/4025 , G01N33/574 , G01N33/5748 , G01N33/57488 , G01N33/57496 , C12Q2600/16 , C12Q2600/106 , C12Q2600/112 , C12Q2600/156 , C12Q2600/158 , G01N2333/82 , G01N2333/515 , G01N2333/916 , G01N2800/52
摘要： The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.
-
公开(公告)号：US11598776B2
公开(公告)日：2023-03-07
申请号：US15934242
申请日：2018-03-23
发明人： Yasuhiro Funahashi , Tadashi Kadowaki , Junji Matsui , Jason S. Simon , Lucy Xu
IPC分类号： G01N33/53 , G01N33/574 , C12Q1/6886 , A61K31/47
摘要： Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.
-
公开(公告)号：US20220117933A1
公开(公告)日：2022-04-21
申请号：US17563162
申请日：2021-12-28
发明人： Taro Semba , Yasuhiro Funahashi , Takuya Suzuki
IPC分类号： A61K31/357 , A61K39/395 , A61P35/00
摘要： A combined administration of a liposomal composition comprising Eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist exhibits unexpected antitumor effect.
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.03 秒)
